[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-treatment-of-migraine\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-treatment-of-migraine":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,64],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100643737","phase-4-a-study-to-learn-about-the-safety-of-taking-an-additional-dose-of-the-medicine-rimegepant-in-adults-with-migraine-100643737",false,"NCT07609914","A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine","A PHASE 4, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFECTIVENESS OF REDOSING OF RIMEGEPANT IN PARTICIPANTS 18 YEARS OF AGE OR OLDER FOR THE ACUTE TREATMENT OF MIGRAINE","Inclusion:\n\n* Eligible participants include adult participants aged 18 years of age or older with a minimum 1-year history of migraine (with or without aura) consistent with International Classification of Headache Disorders, 3rd Edition\n* Eligible participants must be currently using acute migraine treatment in accordance with the local label and have all of the following on average across the 12 weeks prior to the Screening Visit and, during the first 28 days of the observation phase (OP): (1) 6-14 monthly migraine days (MMDs); (2) \\\u003C15 monthly headache days (MHDs) (migraine or non-migraine); and (3) \\\u003C7 monthly non-migraine headache days.\n\nExclusion:\n\n* Participants with headaches occurring ≥15 days per month (migraine or non-migraine) on average across the 12 weeks prior to the Screening Visit and ≥7 non-migraine headache days per month on average across the 12 weeks prior to the Screening Visit would not be eligible.","ALL","18 Years",{"count":19,"type":20},400,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","Acute treatments for migraine may not provide sufficient pain relief after an initial dose, and a second dose of a given medication may be needed to fully abort an attack. International Headache Society (IHS) global practice recommendations for the Acute Treatment of Migraine suggest a second dose of the same medication within the recommended dose limit in people with headache relapse after successful initial treatment of a migraine attack.\n\nThe primary purpose of this study is to evaluate the safety and tolerability of redosing of rimegepant when taken for the acute treatment of a migraine attack, as it is possible that some patients may benefit from a second dose of rimegepant in this setting.",[26],"Acute Treatment of Migraine","RECRUITING","2026-06-29",{"date":30,"type":31},"2026-07-01","ACTUAL",{"date":33,"type":31},"2026-05-28",{"date":35,"type":20},"2028-05-15",{"name":37,"class":38},"Pfizer","INDUSTRY",6,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":57,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100419547","phase-3-long-term-safety-study-of-rimegepant-in-pediatric-subjects-for-the-acute-treatment-of-migraine-100419547","NCT04743141","Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine","Phase 3, Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to \u003C 18 Years of Age","Inclusion Criteria:\n\n1. History of migraine (with or without aura) for ≥ 6 months before Screening.\n2. History of 1 to 8 moderate or severe attacks per month during the 2 months prior to screening.\n3. 1 or more migraine days requiring treatment during the Observation Phase.\n4. Prophylactic migraine medication is permitted if the dose has been stable for at least 12 weeks prior to the Screening Visit.\n5. Ability to distinguish between migraine and other types of headaches.\n6. Weight \\> 15 kg. For EU countries only: Participants 12 to \\\u003C 18 years of age must have a body weight of \\>25kg.\n7. Adequate venous access for blood sampling.\n8. Male and female participants 6 to \\\u003C 18 years of age (participants must not reach their 18th birthday on or before the Baseline visit).\n\nExclusion Criteria:\n\n1. History of cluster headache or hemiplegic migraine headache.\n2. Confounding and clinically significant pain syndrome.\n3. Current uncontrolled and\u002For untreated psychiatric condition for a minimum of 6 months prior to the Screening Visit (lifetime history of psychosis and\u002For mania are excluded).\n4. History of suicidal behavior or at risk of self-harm\u002Fharm to others.\n5. History of major psychiatric disorder.\n6. Current diagnosis or history of substance abuse\n7. Reported current use of or tested positive at Screening for drugs of abuse.","6 Years","17 Years",{"count":50,"type":20},600,[52],"PHASE3","The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to \\\u003C 18 years of age).",[26],[56],"Long-term safety, acute treatment, migraine, phonophobia, photophobia, nausea, pediatric, children, adolescent",{"date":30,"type":31},{"date":59,"type":31},"2021-04-28",{"date":61,"type":20},"2030-07-31",{"name":37,"class":38},126,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":21,"phases":74,"briefSummary":76,"conditions":77,"keywords":78,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},"100592615","phase-1-a-study-to-learn-about-the-study-medicine-called-zavegepant-pf-07930207-in-children-with-a-history-of-migraine-100592615","NCT06995729","A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine","A PHASE 1, MULTICENTER, OPEN-LABEL, SINGLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF ZAVEGEPANT IN CHILDREN 6 TO LESS THAN 12 YEARS OF AGE WITH HISTORY OF MIGRAINE","Inclusion Criteria:\n\n1. Participants aged 6 years to less than 12 years.\n2. Documented medical history of migraine with or without aura for at least 6 months before the Screening Visit.\n3. Weight \\>15 kg at the Screening Visit\n\nExclusion Criteria:\n\n1. Evidence or history of clinically significant disease.\n2. Continuous migraine (defined as an unrelenting headache) within 1 month prior to Screening Visit.\n3. Atypical migraine types, complications of a migraine, or a confounding and clinically significant pain syndrome.\n4. Conditions that may affect the administration or absorption of the nasal product\n5. Any psychiatric condition that is uncontrolled and\u002For untreated, including:\n\n   * Clinically significant depression (Promis Parent Proxy SF 2.0 Depressive Scale T score ≥70)\n   * Suicidal ideation and behaviour (C-SSRS: any \"yes\" to items 2 to 5 or any \"yes\" to suicide behaviours)\n6. Serum Total bilirubin \\>1.5 × ULN (Upper Limit of Normal), AST (Aspartate Transferase) or ALT (Alanine Transaminase) \\>2 × ULN\n7. Abnormal ECG (Electrocardiogram) at screening visit","11 Years",{"count":73,"type":20},16,[75],"PHASE1","The purpose of the study is to learn about safety and how the body processes the study medicine called Zavegepant (PF-07930207) in children with a history of migraine. This study helps understand how the medicine is changed and removed from the body after taking it.\n\nThis study is seeking participants who:\n\n* Are children aged between 6 and less than 12 years old\n* Have had migraine for at least 6 months.\n* Weigh more than 15 kilograms\n\nAll participants in this study will receive zavegepant as a nasal spray once (one spray into one nostril). The dose of the study medicine that each participant receives will depend on how much the participant weighs.\n\nThe study will look at the experiences of the participants receiving the study medicine and collect data to better understand the possible benefits and unwanted effects of different doses of the study medicine.\n\nParticipants will take part in this study for up to 10 weeks. During this time, they will have 3 study visits at the study clinic, and 2 follow-up phone calls.",[26],[79,80,81],"migraine","zavegepant","pediatric","2026-03-16",{"date":84,"type":31},"2026-03-18",{"date":86,"type":31},"2025-05-16",{"date":88,"type":20},"2027-08-12",{"name":37,"class":38},13]